Last updated: 2026-09-16 09:45:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Vyome Holdings, Inc. (HIND) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.07, with a market capitalisation of $14.46M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.75 to $9.56. This page covers its latest market performance, valuation, price trends and company information.
$14.46M | |
$2.06 | |
$16.00 | |
$1.75 | |
$2.06 | |
7.76K | |
12.13K | |
-- | |
$9.56 | |
$1.75 | |
-- | |
-- |
Vyome Holdings, Inc. (HIND) is trading at $2.08 in pre-market trading as of 2026-09-15 23:57:00, up 0.92% ($0.02) from the previous close of $2.06
Pre-market trading shows how investors are pricing HIND before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Vyome Holdings, Inc. (HIND) moved from $2.22 to $2.07, representing a decline of 6.76% ($0.15).
The stock traded between $1.99 and $2.23 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 8.47 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 4.1%
HIND is currently trading at $2.07, placing it 4.1% of the way from its 52-week low of $1.75 to its 52-week high of $9.56. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 18 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vyome Holdings, Inc. (HIND) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.